cash flow reconciliationreview2026-06-30
Operating, investing and financing flows differ from the reported change in cash by 5501000, beyond tolerance 2994810.00.
Figures are reported in CAD, not US dollars, and are shown as filed. Nothing here is converted, so comparing them with a dollar figure compares two different currencies.
Revenue
CAD 307.08M
Fiscal year ended 2026-06-30Operating income
-CAD 161.14M
Fiscal year ended 2026-06-30Free cash flow
-CAD 83.24M
Fiscal year ended 2026-06-30Valuation, from the filing
| Public float | $485.00M | Market value of stock held by non-affiliates, as stated on the cover page for 2025-09-30 |
|---|---|---|
| Float per share | $1.15 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
| Float / revenue | 1.7× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / equity | 0.7× | A lower bound on the multiple, because affiliate holdings are excluded. |
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-09-30, not today, and each multiple below it uses the figures for the fiscal year ending 2026-03-31 — the year that filing covered.
How this compares in its industry
Percentile among the Medicinal Chemicals & Botanical Products filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
| Measure | Reported | Percentile | |
|---|---|---|---|
| Gross margin | 24.5% | 9th | |
| Net margin | -92.4% | 14th | |
| Operating margin | -56.8% | 14th | |
| Current ratio | 3.34x | 84th | |
| FCF margin | -24.3% | 21th | |
| R&D / revenue | 0.9% | 33th | |
| CapEx / revenue | 1.9% | 43th | |
| Revenue YoY growth | 5.8% | 57th | |
| SBC / revenue | 1.5% | 50th |
Canopy Growth Corp (CGC) reported revenue of $307.08M and net income of -$232.63M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Canopy Growth Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Medicinal Chemicals & Botanical Products.
Income
| Metric | 2026-06-30 |
|---|---|
| Revenue | CAD 307.08M |
| Cost of revenue | CAD 219.76M |
| Gross profit | CAD 73.87M |
| Operating income | -CAD 161.14M |
| Net income | -CAD 232.63M |
| Research & development | Unavailable |
| Weighted-average diluted shares | Unavailable |
| Pretax income | -CAD 233.02M |
| Income tax expense | -CAD 397.00K |
| Diluted EPS | Unavailable |
| Selling, general & administrative | CAD 162.10M |
| General & administrative | Unavailable |
| Selling & marketing | Unavailable |
Balance
| Metric | 2026-06-30 |
|---|---|
| Cash & equivalents | CAD 336.62M |
| Total assets | CAD 1.10B |
| Current assets | CAD 506.36M |
| Total liabilities | CAD 415.28M |
| Current liabilities | CAD 166.75M |
| Total equity incl. NCI | CAD 688.63M |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | CAD 107.46M |
| Accounts receivable | CAD 32.55M |
| Goodwill | CAD 55.68M |
| Long-term debt | CAD 211.38M |
| Accounts payable | CAD 28.61M |
Cash flow
| Metric | 2026-06-30 |
|---|---|
| Operating cash flow | -CAD 78.48M |
| Capital expenditures | CAD 4.76M |
| Investing cash flow | -CAD 21.38M |
| Financing cash flow | CAD 299.48M |
| Net change in cash | CAD 210.42M |
| Stock-based compensation | CAD 5.72M |
| Common dividends paid | Unavailable |
| Common share repurchases | Unavailable |
| Depreciation & amortization | Unavailable |
Derived
| Metric | 2026-06-30 |
|---|---|
| Free cash flow | -CAD 83.24M |
| Gross margin | 24.1% |
| Operating margin | -52.5% |
| FCF margin | -27.1% |
| SBC / revenue | 1.9% |
| Current ratio | 3.04x |
| Revenue YoY growth | 6.7% |
| Net margin | -75.8% |
| R&D / revenue | Unavailable |
| CapEx / revenue | 1.6% |
| Long-term debt / equity | 0.31x |
| Effective tax rate | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CGC in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-07View SEC filing
10-K · Filed 2026-06-15View SEC filing
10-Q · Filed 2026-02-06View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-K · Filed 2025-05-30View SEC filing
Reconciliation checks needing review
1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.